Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 3/20 | 0.70 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.70 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.70 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.70 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.70 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.70 |
| ▸ | EGFR | P00533 | 5/20 | 0.65 |
| ▸ | MMP1 | P03956 | 6/20 | 0.63 |
| ▸ | MMP2 | P08253 | 6/20 | 0.63 |
| ▸ | MMP9 | P14780 | 6/20 | 0.63 |
| ▸ | MAOA | P21397 | 1/20 | 0.63 |
| ▸ | MAOB | P27338 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.61 |
| ▸ | GLA | P06280 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | TNKS | O95271 | 1/20 | 0.59 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.59 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.59 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL975355 | 1.00 | HDAC2 (0.70) | HDAC2HDAC3HDAC4HDAC1HDAC8 | |
| Benzene SCHEMBL28260359 | 1.00 | HDAC2 (0.70) | HDAC2HDAC3HDAC4HDAC1HDAC8 | |
| SCHEMBL7369073 | 0.98 | HDAC2 (0.68) | HDAC2HDAC3HDAC4HDAC1HDAC8 | |
| SCHEMBL30435616 | 0.83 | ALDH1A1 (0.52) | HDAC2HDAC3HDAC4HDAC1HDAC8 | |
| SCHEMBL29060766 | 0.83 | HDAC2 (0.76) | HDAC2HDAC3HDAC4HDAC1HDAC8 | |
| SCHEMBL11704206 | 0.83 | HDAC3 (0.76) | HDAC2HDAC3HDAC4HDAC1HDAC8 | |
| SCHEMBL4029206 | 0.83 | HDAC2 (0.76) | HDAC2HDAC3HDAC4HDAC1HDAC8 | |
| SCHEMBL1325253 | 0.83 | HDAC2 (1.00) | HDAC2HDAC3HDAC4HDAC1HDAC8 | |
| SCHEMBL559917 | 0.83 | HDAC2 (1.00) | HDAC2HDAC3HDAC4HDAC1HDAC8 | |
| SCHEMBL11704209 | 0.83 | HDAC3 (0.76) | HDAC2HDAC3HDAC4HDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108041049-A | A kind of compounded pesticides and its preparation method and application | 广东省林业科学研究院 | 2018-05-18 | — | — | CN | claimed |
| CN-104432097-A | Natural enriching substance for relieving physical fatigue | DUAN ZHANE | 2015-03-25 | — | — | CN | claimed |
| CN-101045697-B | Clausena lansium stone extraction and preparation method thereof | UNIV JINAN | 2010-12-15 | — | — | CN | claimed |
| CN-101045697-A | Clausena lansium stone extraction and preparation method thereof | UNIV JINAN (CN) | 2007-10-03 | — | — | CN | claimed |
| US-4226864-A | BACTERICIDES, ANTIBIOTICS | SHIONOGI & CO., LTD. (JP) | 1980-10-07 | — | — | US | claimed |
| US-20250032448-A1 | COMPOUND FOR USE IN THE TREATMENT AND/OR PREVENTION OF PARASITIC MEDIATED DISEASES | KOH, Hwee Ling (SG) | 2025-01-30 | — | — | US | disclosed |
| US-12144797-B2 | Compound for use in the treatment and/or prevention of parasitic mediated diseases | KOH, Hwee Ling (SG) | 2024-11-19 | — | — | US | disclosed |
| CN-113462278-B | Varnish composition, method for producing polyimide resin, and additive | 东京应化工业株式会社 | 2024-06-07 | — | — | CN | disclosed |
| US-20230301984-A1 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230295236-A1 | COMPOUNDS FOR USE IN INFLAMMATORY CONDITIONS | PHARMA MAR, S.A. (ES) | 2023-09-21 | — | — | US | disclosed |
| CN-113462278-A | Varnish composition, method for producing polyimide resin, and additive | 东京应化工业株式会社 | 2021-10-01 | — | — | CN | disclosed |
| US-20210163423-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2021-06-03 | — | — | US | disclosed |
| EP-0406958-B1 | Positive inotropic and lusitropic 3,5-dihydroimidazo[2,1-b]quinazolin-2(1H)-one derivatives | JANSSEN PHARMACEUTICA NV (BE) | 1995-03-15 | — | — | EP | disclosed |
| CN-1097417-A | New heterogeneous ring compound | FUJISAWA PHARMACEUTICAL CO (JP) | 1995-01-18 | — | — | CN | disclosed |
| EP-0623614-A1 | 4-Aryl-4-hydroxy-tetrahydropyrans and 3-aryl-3-hydroxy-tetrahydrofurans as 5-lipoxygenase inhibitors | ZENECA LIMITED (GB) | 1994-11-09 | — | — | EP | disclosed |
| EP-0622361-A1 | Heterocyclic compounds as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-11-02 | — | — | EP | disclosed |
| CN-1089947-A | New heterogeneous ring compound | FUJISAWA PHARMACEUTICAL CO (JP) | 1994-07-27 | — | — | CN | disclosed |
| EP-0596406-A1 | Imidazo (1,2-a) Pyridines as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-05-11 | — | — | EP | disclosed |
| EP-0406958-A2 | Positive inotropic and lusitropic 3,5-dihydroimidazo[2,1-b]quinazolin-2(1H)-one derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-01-09 | — | — | EP | disclosed |
| US-4226864-A | BACTERICIDES, ANTIBIOTICS | SHIONOGI & CO., LTD. (JP) | 1980-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295236-A1 | COMPOUNDS FOR USE IN INFLAMMATORY CONDITIONS | TLR4, TLR3, TLR2 | HDAC2 753/4885HDAC3 651/4885HDAC4 802/4885 |
| US-20210163423-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, PIK3CA, PLK1 | HDAC2 808/4885HDAC3 827/4885HDAC4 1128/4885 |
| US-12144797-B2 | Compound for use in the treatment and/or prevention of parasitic mediated diseases | ICMT, ALG3, PFN1 | HDAC2 2746/4885HDAC3 1357/4885HDAC4 3034/4885 |
| US-20230301984-A1 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | ALDH1A2, PDE6D, PDE6C | HDAC2 263/4885HDAC3 243/4885HDAC4 617/4885 |
| US-20250032448-A1 | COMPOUND FOR USE IN THE TREATMENT AND/OR PREVENTION OF PARASITIC MEDIATED DISEASES | EPX, PKD2, MPO | HDAC2 913/4885HDAC3 1023/4885HDAC4 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.